New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
08:41 EDTMDVNMedivation weakness a buying opportunity, says UBS
UBS said Medivation weakness from the PREVAIL presentation is a buying opportunity and said its Q4 urology survey indicates topline PREVAIL data will drive robust utilization. Shares are Buy rated with a $93 price target.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use